327 related articles for article (PubMed ID: 9711054)
1. [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase].
Stichtenoth DO; Zeidler H; Frölich JC
Med Klin (Munich); 1998 Jul; 93(7):407-15. PubMed ID: 9711054
[TBL] [Abstract][Full Text] [Related]
2. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
Blain H; Jouzeau JY; Netter P; Jeandel C
Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacology of non-steroidal anti-inflammatory drugs and ENT pathology].
Devillier P
Presse Med; 2001 Dec 22-29; 30(39-40 Pt 2):70-9. PubMed ID: 11819916
[TBL] [Abstract][Full Text] [Related]
4. The second generation of COX-2 inhibitors: what advantages do the newest offer?
Stichtenoth DO; Frölich JC
Drugs; 2003; 63(1):33-45. PubMed ID: 12487621
[TBL] [Abstract][Full Text] [Related]
5. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Dequeker J; Isomäki H; Littlejohn G; Mau J; Papazoglou S
Br J Rheumatol; 1998 Sep; 37(9):937-45. PubMed ID: 9783757
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
Meyer-Kirchrath J; Schrör K
Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
[TBL] [Abstract][Full Text] [Related]
8. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
Bertolini A; Ottani A; Sandrini M
Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
[TBL] [Abstract][Full Text] [Related]
9. Meloxicam: selective COX-2 inhibition in clinical practice.
Furst DE
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):21-7. PubMed ID: 9219316
[TBL] [Abstract][Full Text] [Related]
10. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory drugs in the 21st century.
Rainsford KD
Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
[TBL] [Abstract][Full Text] [Related]
12. New directions in cyclooxygenase research and their implications for NSAID-gastropathy.
Flower RJ
Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():23-7. PubMed ID: 9032578
[TBL] [Abstract][Full Text] [Related]
13. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
Galli G; Panzetta G
G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
[TBL] [Abstract][Full Text] [Related]
14. [Non-steroidal anti-inflammatory drugs and cyclooxygenase-2 selectivity in gastroenterology].
Ledro Cano D; Gómez Rodríguez BJ; Torres Domínguez Y; Hergueta Delgado P; Herrerías Esteban JM; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 1999 Apr; 91(4):305-9. PubMed ID: 10348929
[TBL] [Abstract][Full Text] [Related]
15. Current perspective on the cardiovascular effects of coxibs.
Konstam MA; Weir MR
Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
[TBL] [Abstract][Full Text] [Related]
16. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
Peura DA
Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
[TBL] [Abstract][Full Text] [Related]
18. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
Joshua FF; Oakley SP; Major GA
Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
[TBL] [Abstract][Full Text] [Related]
19. Selective cyclooxygenase-2 inhibitors: similarities and differences.
Brune K; Hinz B
Scand J Rheumatol; 2004; 33(1):1-6. PubMed ID: 15124935
[TBL] [Abstract][Full Text] [Related]
20. Scientific rationale for specific inhibition of COX-2.
Bolten WW
J Rheumatol Suppl; 1998 May; 51():2-7. PubMed ID: 9596548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]